Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acyl ghrelin + desacyl ghrelin is a combination of the two major circulating isoforms of the peptide hormone ghrelin. Acylated (AG) and desacyl (DAG) forms have distinct biological activities. Acyl ghrelin acts as an agonist at the growth hormone secretagogue receptor (GHSR-1a), stimulating appetite, adiposity, and growth hormone release. Desacyl ghrelin does not bind GHSR-1a but exerts independent effects on metabolism and cell differentiation through other mechanisms or possibly novel receptors. The combination has been shown to modulate insulin sensitivity and glucose metabolism more favorably than acylated form alone in human studies[1][2]. Both forms also promote skeletal muscle differentiation via p38 activation independently of GHSR-1a[4][6]. This combination is under investigation for its potential roles in metabolic disorders, muscle wasting conditions, and cardiovascular diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acyl ghrelin + desacyl ghrelin.